ML210 Antagonizes ABCB1- Not ABCG2-Mediated Multidrug Resistance in Colorectal Cancer
<b>Objectives:</b> ABCB1-mediated multidrug resistance (MDR) compromises chemotherapy efficacy in colorectal cancer (CRC). Despite decades of research, no selective ABCB1 inhibitor has achieved clinical success. This study investigates ML210 as a novel ABCB1-specific inhibitor to reverse...
Saved in:
| Main Authors: | Yan-Chi Li, Yu-Meng Xiong, Ze-Ping Long, Yi-Ping Huang, Yu-Bin Shu, Ke He, Hong-Yan Sun, Zhi Shi |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-05-01
|
| Series: | Biomedicines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2227-9059/13/5/1245 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Preclinical studies of the falnidamol as a highly potent and specific active ABCB1 transporter inhibitor
by: Baojie Liu, et al.
Published: (2025-01-01) -
Association of <i>ABCG5</i> and <i>ABCG8</i> Polymorphisms with Gallstone Disease and Gallbladder Cancer
by: I. N. Grigor’eva, et al.
Published: (2025-06-01) -
Reversal of ABCG2-mediated drug resistance by tinodasertib (ETC-206)
by: Haigan Yang, et al.
Published: (2025-06-01) -
Correction: Reversal of ABCG2-mediated drug resistance by tinodasertib (ETC-206)
by: Haigan Yang, et al.
Published: (2025-08-01) -
Molecular design, synthesis and biological evaluation of novel 1,2,5-trisubstituted benzimidazole derivatives as cytotoxic agents endowed with ABCB1 inhibitory action to overcome multidrug resistance in cancer cells
by: Abeer H. A. Abdelhafiz, et al.
Published: (2022-12-01)